CN101267828A - 用于共同递送抗癌药、抗血管生成药和多糖的组合物及方法 - Google Patents

用于共同递送抗癌药、抗血管生成药和多糖的组合物及方法 Download PDF

Info

Publication number: CN101267828A
Authority: CN; China
Prior art keywords: compositions; polysaccharide; acid; main chain; cancer
Prior art date: 2004-06-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CNA2005800207078A

Other languages

English (en)

Chinese (zh)

Inventor

D·普拉特

E·佐默

A·科尔约瑟夫

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pro Pharmaceuticals Inc

Original Assignee

Pro Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-22

Filing date

2005-06-21

Publication date

2008-09-17

2005-06-21 Application filed by Pro Pharmaceuticals Inc filed Critical Pro Pharmaceuticals Inc

2008-09-17 Publication of CN101267828A publication Critical patent/CN101267828A/zh

Status Pending legal-status Critical Current

Links

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Zoology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

CNA2005800207078A 2004-06-22 2005-06-21 用于共同递送抗癌药、抗血管生成药和多糖的组合物及方法 Pending CN101267828A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US58195804P	2004-06-22	2004-06-22
US60/581,958		2004-06-22

Publications (1)

Publication Number	Publication Date
CN101267828A true CN101267828A (zh)	2008-09-17

Family

ID=35782284

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNA2005800207078A Pending CN101267828A (zh)	2004-06-22	2005-06-21	用于共同递送抗癌药、抗血管生成药和多糖的组合物及方法

Country Status (6)

Country	Link
EP (1)	EP1765365A4 (de)
JP (1)	JP2008503583A (de)
CN (1)	CN101267828A (de)
BR (1)	BRPI0512394A (de)
CA (1)	CA2570570A1 (de)
WO (1)	WO2006002106A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106456765A (zh) *	2014-06-18	2017-02-22	法国血液分割暨生化制品实验室	抗TNFα抗体的口服组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2723987C (en)	2008-05-14	2019-06-11	Agriculture Victoria Services Pty Ltd	Use of angiogenin or angiogenin agonists for treating diseases and disorders
AU2013204721B2 (en) *	2008-05-14	2016-08-18	Agriculture Victoria Services Pty Ltd	Methods for treating cachexia
CZ302789B6 (cs)	2009-11-25	2011-11-09	Zentiva, K. S.	Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
AU2013204740C1 (en) *	2012-05-10	2015-10-01	Agriculture Victoria Services Pty Ltd	Methods of treating cancer using angiogenin or an angiogenin agonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5308838A (en) *	1982-05-07	1994-05-03	Carrington Laboratories, Inc.	Uses of aloe products
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
US20020107222A1 (en) *	1993-03-01	2002-08-08	David Platt	Modified polysaccharides for treatment of cancer
US5834442A (en) *	1994-07-07	1998-11-10	Barbara Ann Karmanos Cancer Institute	Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
EP0958825A1 (de) *	1998-05-18	1999-11-24	Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.)	Synergistische Zusammensetzung zur Behandlung von Krebs, welche unverdauliche Kohlenhydrate und eines Antikrebsmittel enthält
DE50012701D1 (de) *	1999-09-06	2006-06-08	Guenther Beisel	Vernetztes mittel zur erzeugung eines langanhaltenden sättigungseffekts und verfahren zu dessen herstellung
US7012068B2 (en) *	2001-03-27	2006-03-14	Pro-Pharmaceuticals, Inc.	Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
KR20040045795A (ko) *	2002-11-25	2004-06-02	주식회사한국신약	펠리누스 린테우스에서 추출한 다당류와 마이토마이신ｃ를 포함하는 복합 항암제

2005
- 2005-06-21 WO PCT/US2005/021827 patent/WO2006002106A2/en not_active Ceased
- 2005-06-21 EP EP05786102A patent/EP1765365A4/de not_active Withdrawn
- 2005-06-21 CN CNA2005800207078A patent/CN101267828A/zh active Pending
- 2005-06-21 JP JP2007518186A patent/JP2008503583A/ja active Pending
- 2005-06-21 BR BRPI0512394-1A patent/BRPI0512394A/pt not_active IP Right Cessation
- 2005-06-21 CA CA002570570A patent/CA2570570A1/en not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106456765A (zh) *	2014-06-18	2017-02-22	法国血液分割暨生化制品实验室	抗TNFα抗体的口服组合物

Also Published As

Publication number	Publication date
EP1765365A2 (de)	2007-03-28
JP2008503583A (ja)	2008-02-07
BRPI0512394A (pt)	2008-03-11
CA2570570A1 (en)	2006-01-05
WO2006002106A2 (en)	2006-01-05
EP1765365A4 (de)	2008-02-20
WO2006002106A3 (en)	2006-10-19

Similar Documents

Publication	Publication Date	Title
AU2019310656B2 (en)	2022-03-10	Highly sulfated fucans for the treatment of fibrous adhesions
US8071569B2 (en)	2011-12-06	Oxidized heparin fractions and their use in inhibiting angiogenesis
Chi et al.	2019	Synthesis and anti-metastasis activities of norcantharidin-conjugated carboxymethyl chitosan as a novel drug delivery system
EP0355088B1 (de)	1997-12-10	Sulfatierte polysaccharide mit antimetastasenwirkung
JP5371167B2 (ja)	2013-12-18	抗脈管形成活性を有し、かつ、抗凝固作用がない、部分脱硫酸グリコサミノグリカンの誘導体
US5895784A (en)	1999-04-20	Method for treatment of cancer by oral administration of modified pectin
US7638127B2 (en)	2009-12-29	Peptide conjugated anti-cancer prodrugs
ES2431362T3 (es)	2013-11-26	Derivados de glicosaminoglicanos totalmente N-desulfatados como agentes inhibidores de la heparanasa, dotados con actividad antiangiogénica y desprovistos de efecto anticoagulante
EA001199B1 (ru)	2000-12-25	Сульфатированный олигосахарид, его применение для лечения теплокровных животных и фармацевтическая композиция на его основе
US20020107222A1 (en)	2002-08-08	Modified polysaccharides for treatment of cancer
Cai et al.	2019	Design and synthesis of a native heparin disaccharide grafted poly‑2‑aminoethyl methacrylate glycopolymer for inhibition of melanoma cell metastasis
ES2458818T3 (es)	2014-05-07	Métodos para evaluar la actividad de una composición de polisacárido
CN101267828A (zh)	2008-09-17	用于共同递送抗癌药、抗血管生成药和多糖的组合物及方法
EP1734819A1 (de)	2006-12-27	Zusammensetzungen und verfahren für das targeting von metastasierenden tumoren mit hilfe von mehrwertigen ligandgebundenen kohlenhydratpolymeren
JP6444399B2 (ja)	2018-12-26	癌の処置に用いるための硫酸化多糖
US20050282773A1 (en)	2005-12-22	Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
EP1501522A2 (de)	2005-02-02	Vorblockierung mit nicht-ha gags erhöht die wirksamkeit von ha-konjugierten krebsmitteln
EP1592432A2 (de)	2005-11-09	Modifizierte polysaccharide in kombination mit antikrebswirkstoffen für verstärkte krebsbehandlung
ITMI20010779A1 (it)	2002-10-12	Uso di polisaccaridi batterici solfati atti all'inibizione dell'angiogenesi
WO2021128253A1 (zh)	2021-07-01	一种糖胺聚糖衍生物及其应用
RU2412712C1 (ru)	2011-02-27	Противовоспалительное средство с антикоагулянтной, противоопухолевой и антиметастатической активностью
Beiner	2025	Anti-Cancer Activity of Marine-Derived Fucosylated Chondroitin Sulfates in Ovarian Cancer Cell Spheroid Formation and Notch Signaling Inhibition
JP2024523679A (ja)	2024-06-28	抗癌特性を有する低分子量ｈｅ８００エキソ多糖誘導体及びその使用
박주호	2016	Design and therapeutic evaluation of heparin based bioconjugate for oral delivery and antiangiogenic therapy
정성우	2015	Design and development of multi-targeted anticancer agents for anti-angiogenic therapy or tumor tissue-selective delivery

Legal Events

Date	Code	Title	Description
2008-09-17	C06	Publication
2008-09-17	PB01	Publication
2008-11-05	C10	Entry into substantive examination
2008-11-05	SE01	Entry into force of request for substantive examination
2011-02-02	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2011-02-02	WD01	Invention patent application deemed withdrawn after publication	Open date: 20080917